SCHEMBL6409215

SCHEMBL6409215

CNCCc1ccc(NC(C)C=C2C(=O)Nc3cc(OC)c(OC)cc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 6/20 0.43
TLK2 Q86UE8 3/20 0.42
POLB P06746 1/20 0.41
ATM Q13315 1/20 0.41
BRD4 O60885 2/20 0.38
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
GSK3B P49841 2/20 0.35
FLT3 P36888 2/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35
NOX4 Q9NPH5 1/20 0.34
HTR1A P08908 1/20 0.34
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
HTR2A P28223 1/20 0.34
HTR1E P28566 1/20 0.34
HTR7 P34969 1/20 0.34
HTR2B P41595 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6330676 0.90 RET (0.42) RETTLK2BRD4MEN1MAPT
SCHEMBL6778312 0.90 RET (0.45) RETTLK2BRD4GSK3BFLT3
SCHEMBL6329073 0.89 RET (0.44) RETTLK2ATMBRD4GSK3B
SCHEMBL6331267 0.89 RET (0.45) RETTLK2POLBGSK3BFLT3
SCHEMBL6337029 0.87 RET (0.43) RETTLK2BRD4GSK3BFLT3
SCHEMBL6337433 0.87 RET (0.43) RETTLK2BRD4GSK3BFLT3
SCHEMBL6329102 0.87 RET (0.45) RETTLK2BRD4GSK3BFLT3
SCHEMBL6336918 0.85 RET (0.46) RETTLK2BRD4GSK3BFLT3
SCHEMBL6336955 0.85 PSEN1 (0.43) RETTLK2BRD4FLT3HTR1A
SCHEMBL6329628 0.85 RET (0.41) RETTLK2BRD4FLT3KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments CCNE1, CDK1, CCNI RET 154/4885TLK2 1364/4885POLB 2055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.